Nocioceptive Pain. Inflammatory Pain. Nociceptive Pain. Inflammatory Pain. Neuropathic Pain
|
|
- Laureen Williams
- 6 years ago
- Views:
Transcription
1 Nocioceptive Pain Pathophysiology of Pain Larry Levine, MD Alaska Spine Institute Ex: Acute Postoperative Pain Noxious peripheral Stimuli Heat/Cold Mechanical Force Chemical Irritants Nociceptive Pain Inflammatory Pain Noxious peripheral Stimuli Nociceptor sensory Neuron Pain Autonomic response, Withdrawal Reflex Spinal Cord and Brain A High Pain Threshold Response Ex: active RA, acute OA flare Inflammation Macrophage Mast Cell Neutrophil Granulocyte Tissue Damage Inflammatory Pain Neuropathic Pain Spontaneous Pain Pain Hypersensitivity Reduced Threshold allodynia Increased Response Hyperalgesia Ex: Diabetic Peripheral Neuropathic Pain Post Herpetic Neuralgia 1
2 Neuropathic Pain Peripheral Nerve Damage Spontaneous Pain / Pain Hypersensitivity Reduced Threshold: allodynia Increased response: hyperalgesia Pain Associated with Central Augmentation Fibromyalgia Pain Associated with Central Augmentation Normal Peripheral Tissue and Nerves*** Abnormal Central Processing in Spinal Cord and Brain Spontaneous Pain/ Pain Hypersensitivity Allodynia / Hyperalgesia Action Sites: Peripheral Nocioceptors Transduction Acetaminophen anticonvulsants ASA Capsaicin Local Anesthetics Nitrates NSAIDS Action Site: Transmission, Peripheral Nerve Action:Transmission, DRG, Dorsal Horn Local Anesthetics Opiods alpha 2 agonists, local anesthetics 2
3 Action: Modulation, Brain Stem, Cord (Descending Modulation) SNRI s, SSRI s, Local Anesthetics Action: Perception, Brain alpha 2 adrenergic agonists opiods SNRI s SSRI s TCA s Pain Nociception An unpleasant sensory and emotional experience which we primarily associate with tissue damage or describe in terms of such damage, or both The detection of tissue damage by specialized transducers connected to A-delta and C-fibers Classification of Pain Nociception Classification of Pain: Neuropathic Pain Proportionate to the stimulation of the nociceptor When acute Physiologic pain Serves a protective function Normal pain Pathologic when chronic Sustained by aberrant processes in PNS or CNS Disproportionate to the stimulation of nociceptor Serves no protective function Pathologic pain 3
4 Classification of Pain: Mixed Pain Classification of Pain: Idiopathic Pain Nociceptive components Neuropathic components Examples Failed low-back-surgery syndrome Complex regional pain syndrome No underlying lesion found yet, despite investigation Pain disproportionate to the degree of clinically discernible tissue injury Peripheral and Central Pathways for Pain Ascending Tracts Descending Tracts Normal Central Pain Mechanisms Thalamus Cortex Midbrain Pons Medulla Spinal Cord Pain-Inhibitory and Pain-Facilitatory Mechanisms Within the Dorsal Horn Neuronal circuitry within the dorsal horn. Primary afferent neuron axons synapse onto spinothalamic neurons and onto inhibitory and excitatory neurons. 0 A- BETA A- DELTA + STT + NEURON + + TO BRAIN C Mechanisms of Pathologic Pain 4
5 Mechanisms of Pathophysiologic Pain: Peripheral Processes Mechanisms of Pathophysiologic Pain: Central Sensitization Processes Injured or diseased nerve(s) Growth of axonal sprouts Formation of ectopic foci Repeated impulse activity in C nociceptive neurons produces sensitization of STT neurons over time Sensitization of STT neurons leads to Increased spontaneous impulse activity Enhanced responses to impulses in nociceptive and non-nociceptive primary afferents Causes hyperalgesia, allodynia, and spontaneous pain Mechanism of Central Sensitization Associated With Tonic C Nociceptor Input 0 A- BETA A- DELTA + STT NEURON TO BRAIN C Tonic activity in C nociceptors Enhanced postsynaptic effects by NMDA-receptor sensitization Intracellular Mechanisms of Sensitization Reproduced with permission from Mao J, et al. Pain. 1995;61:361. Loss of Inhibitory Interneuron Function 0 A- BETA A- DELTA + STT NEURON TO BRAIN C Tonic activity in C nociceptors Enhanced postsynaptic effects by NMDA-receptor sensitization Brain-to-Spinal-Cord Modulation of Pain 5
6 Pain Modulation Mechanisms Pathophysiology of Pain: Conclusion Brain centers/pathways that descend to the spinal cord and modulate pain Tail-flick test Off-cells inhibit transmission of pain-related information to the brain On-cells facilitate transmission of painrelated signals to the brain Neuronal plasticity Nociceptor, spinal cord, brain Pain-facilitatory and pathophysiologic mechanisms Wind-up phenomenon Central sensitization Modulating mechanisms Ascending Descending Nociceptive Pain Sensitization and activation of healthy nociceptor endings and recruitment of silent nociceptors Soup of inflammatory algogenic agents, such as protons, prostaglandins, bradykinin, serotonin, adenosine, histamine, cytokines Neuropathic Pain Mechanisms of Neuropathic Pain Pathophysiology of Neuropathic Pain Noninflammatory states Inflammatory states Ectopic activity in the peripheral pathways, including axons and DRG CNS mechanisms 6
7 Neuropathic Pain: Central Mechanisms Peripheral neuropathic events can be complicated by temporary or long-term CNS changes, such as central sensitization and then reorganization of the pain pathways at the dorsal horn level Neuropathic Pain and SMP Some neuropathic pains are sustained, at least in part, by sympathetic efferent activity SMP Expression of alpha-adrenergic receptors on injured C-fibers may be a relevant mechanism of SMP, but others are possible Clinical findings consistent with CRPS signal an increased likelihood of SMP PNS peripheral nervous system CNS central nervous system Nociceptive Pain Healthy nociceptors Peripheral sensitization Normal Central transmission sensitization Pappagallo M Physiologic state Neuropathic Pain Abnormal nociceptors PNS Central reorganization Pathologic state CNS Neuropathic Pain Diverse syndromes with uncertain classification Mononeuropathies and polyneuropathies CRPS Deafferentation syndromes, including central pain Fibromyalgia as a Clinical Model for Pharmacology of Pain Pathogenesis Higher levels Nitric Oxide Lower Phosphorylation Potential Lower Oxidative Capacity Thus lower levels ATP Increased Levels Substance P, IL -1 > DNA Fragmentation Perfusion Deficits Appears to represent difference in muscle metabolism 7
8 Neural Structure Changes NMDA N-methyl-D-Aspartate receptor changes Glutamate binds to NR2 Subunits of NMDA in the DRG and skin Upregulation of subunits in those with fibromyalgia(159 vs 100 p=0.016) Electron microscopy shows Schwann Cell fiber ballooning, axon peripheralization, smaller axon size, simplified folding structures Changes in opiod receptors: up regulation of delta and kappa receptors. Neuroendocrine changes decreased response to ACTH, epi under stresses CSF Changes in Biochemicals Lower serum serotonin levels Lower norepinepherine levels Lower dopamine levels Higher substance P levels Higher Nerve Growth Factor levels Possible candidate genes related to FMS HLA DR4 antigen D2 and D4 Dopamine receptors on chrom 11 Substance P receptor (NK1) Symptoms with FMS Symptoms with FMS Neuro < concentration Dizziness Headache Psychiatric Anxiety Depression Fear, anger, guilt GI Abd Pain Bloating Constipation Diarrhea GU Pelvic Pain Urinary Burning, Frequency 8
9 Symptoms with FMS FMS Constitutional Symptoms Fatigue/Generalized Weakness Night Sweats Weight Fluctuations Functional MRI coorelates Changes noted but what does it mean still up for discussion: clear alteration in processing of pain. Medications: Antiepileptic TCA SSRI SNRI Analgesic Muscle Relaxants 1st Line Cyclobenzaprine Duloxetine(Cymbalta) Milnacipran (Savella) Pregabalin (Lyrica) TCA s amitriptyline 2nd Line SSRI (fluoxetine Prozac, citalopram Celexa) Tramadol Venlafaxine (Effexor) Not Recommeded Benzos Calcitonin Guaifenesin Melatonin NSAID s Opiods Steroids Thyroid Hormone 9
10 Nonpharmacological Treatments 1st Line Aerobic Exercise Cognitive Behavioral Therapy Patient Education 2nd Line Acupuncture Biofeedback Hypnotherapy Strength Training Nonpharmacological 3 rd Line Chiropractic Electrotherapy Massage Ultrasound Diagnosing and Treating Fibromyalgia: Present and Future Considerations. Bernstein, Marcus, Pain Medicine News, December 2009 Opiod Considerations Strong Relationship between THCA positivity and other illicit substances. Pain Practice 13% THCA > 3.7 ration of other illicit drugs in those THCA positive including cocaine 4.6 % total, methamphetamine 1.07% Marijuana Correlates with Use of Other Illicit Drugs in a Pain Patient Population, Pesce et al, Pain Physician 2010 Opiod Considerations Neuropathic Pain: Clinical Characteristics Benzos Predict Use of Opioids A Follow-UP Study of Men and Women, Skurtveit et al, Pain Medicine 2010;11 Earlier use of benzodiazepines may predict repeated use of opiods. Odds ratio for opiod use at moderate-high prescription frequency is 7.7 (95% confidence interval) as compared with non users. Use of benzos is stronger predictor of opiod use then self reported chronic pain. Burning, shooting, electrical-quality pain May be aching, throbbing, sharp Neuropathic sensations: dysesthesias, paresthesias 10
11 Neuropathic Sensations Paresthesias: abnormal; spontaneous, intermittent, painless Dysesthesias: abnormal; spontaneous or touch-evoked, unpleasant Neuropathic Pain: Evoked Dysesthesias Allodynia: pain elicited by a nonnoxious stimulus (clothing, air movement, touch) Mechanical (induced by light pressure) Thermal (induced by a nonpainful cold or warm stimulus) Hyperalgesia: exaggerated pain response to a mildly noxious (mechanical or thermal) stimulus Hyperpathia: delayed and explosive pain response to a noxious stimulus Primary Hyperalgesia Secondary Hyperalgesia Present in the primary zone, at the location of injury Characterized by pinprick hyperalgesia + warm and heat hyperalgesia + static mechanical allodynia (tenderness) Indicative of PNS sensitization Present in the zone surrounding an injury Characterized by dynamic mechanical allodynia + cold hyperalgesia Indicative of CNS sensitization Neuropathic Pain: Management Neuropathic Pain: Pharmacologic Therapies Pharmacotherapy Nonopioid Opioid Adjuvant analgesics Interventional Neural blockade (eg, sympathetic nerve blocks) Neurostimulatory techniques (eg, spinal cord stimulation) Intraspinal infusion Gabapentin, carbamazepine, lamotrigine, and newer AEDs Antidepressants Opioid analgesics Lidocaine (transdermal, intravenous [IV]), mexiletine Alpha-2 adrenergic agonists 11
12 Disk Herniation With Sciatica 90% of ruptured disks at L4-L5 and L5- S1 90% of patients with back pain and sciatica will recover without surgery At least 50% within 6 wk Low Back Pain and Sciatica: Nociceptive/ Inflammatory Pain Mechanisms Activation and sensitization of the nerve root nervi nervorum from root compression/traction Sensitization of the nociceptors of the annulus fibrosus, periosteal spinal structures, and ligaments, due to acute inflammation, eg, status post trauma Hyperalgesia (deep spinal and dermatomal) due to central sensitization Radicular and Discogenic Neuropathic Pain Mechanisms Ectopic activity of the nerve root nervi nervorum Sensitization and ectopic activity of the nociceptors innervating spinal periosteal structures, ie, annuli and ligaments Possible role of abnormal nociceptors overgrown within the intradiscal space, postsurgical epidural scars, degenerated facet joints CNS sensitization and reorganization Failed-Back-Surgery Syndrome Reoperations 60% due to post spinal surgery complications 40% due to uncorrected or new structural abnormalities of the spine Failed-Back-Surgery Syndrome Management of Back Pain Postsurgical causes of back pain Recurrent or retained disk fragment Postoperative instability Dural adhesions Root injury Arachnoiditis Pseudomeningocele Failure to relieve the original pathologic condition Postoperative wound and disk infection Pharmacologic agents Opioid analgesics Anti-inflammatories Adjuvants and nonopioid analgesics Nonpharmacologic therapies Rehabilitative Interventional 12
13 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Acetaminophen Inhibition of cyclooxygenase activity COX-1 and COX-2 drugs Toxicity: Gastrointestinal, renal, platelet aggregation Multiple drugs Ceiling dose effect Peripheral and central analgesic action Minimal anti-inflammatory action Central analgesia No GI or platelet-aggregation toxicity Serious dose-dependent hepatotoxicity Ceiling dose effect Nonopioid Adjuvant Analgesics Antidepressants TCAs (nortriptyline, amitriptyline, desipramine) SSRIs (paroxetine, sertraline, fluoxetine) Venlafaxine Alpha 2-adrenergic agonists TCA = tricyclic antidepressant; SSRI = selective serotonin reuptake inhibitor Tizanidine, clonidine Nonopioid Adjuvant Analgesics Gabapentin Carbamazepine Clonazepam Valproate Antiepileptics and Antiarrhythmics Lamotrigine Tiagabine Topiramate Oxcarbazepine Zonisamide Mexiletine Pharmacotherapy for Pain Pharmacotherapy of Pain Categories of analgesic drugs Opioid analgesics Nonopioid analgesics Adjuvant analgesics Drugs for headache 13
14 Evolving Role of Opioid Therapy Positioning Opioid Therapy Historically, opioids have been emphasized in medical illness and de-emphasized in nonmalignant pain Consider as first-line for patients with moderate-tosevere pain related to cancer, AIDS, or another life-threatening illness Consider for all patients with moderate-to-severe noncancer pain, but weigh the influences What is conventional practice? Are opioids likely to work well? Are there reasonable alternatives? Are drug-related behaviors likely to be responsible, or problematic so as to require intensive monitoring? Opioid Therapy: Prescribing Principles Opioid Therapy: Drug Selection Prescribing principles Drug selection Dosing to optimize effects Treating side effects Managing the poorly responsive patient Immediate-release preparations Used mainly For acute pain For dose finding during initial treatment of chronic pain For rescue dosing Can be used for long-term management in select patients Opioid Therapy: Drug Selection Opioid Therapy: Drug Selection Immediate-release preparations Combination products Acetaminophen, aspirin, or ibuprofen combined with codeine, hydrocodone, dihydrocodeine Single-entity drugs, eg, morphine, oxycodone, oxymorphone, others Tramadol Extended-release preparations Preferred because of improved treatment adherence and the likelihood of reduced risk in those with addictive disease Morphine, oxycodone, oxymorphone, fentanyl, hydromorphone, codeine, tramadol, buprenorphine 14
15 Opioid Therapy: Drug Selection Opioid Selection: Poor Choices for Chronic Pain Role of methadone Another useful long-acting drug Unique pharmacology when commercially available as the racemic mixture Potency greater than expected based on single-dose studies When used for pain: multiple daily doses, steady-state in 1 to several weeks Close monitoring needed until steady-state approached to reduce risk of side effects Meperidine Poor absorption and toxic metabolite Propoxyphene Poor efficacy and toxic metabolite Mixed agonist-antagonists (pentazocine, butorphanol, nalbuphine, dezocine) Compete with agonists withdrawal Analgesic ceiling effect Opioid Therapy: Routes of Administration Opioid Therapy: Guidelines Oral and transdermal preferred Oral transmucosal available for fentanyl and used for breakthrough pain Rectal route limited use Parenteral SQ and IV preferred and feasible for long-term therapy Intraspinal intrathecal generally preferred for long-term use Consider use of a long-acting drug and a rescue drug usually 5% 15% of the total daily dose Baseline dose increases: 25% 100% or equal to rescue dose use Increase rescue dose as baseline dose increases Treat side effects Opioid Therapy: Side Effects Nonopioid Analgesics Common Constipation Somnolence, mental clouding Less common Nausea Sweating Myoclonus Amenorrhea Itch Sexual dysfunction Urinary retention Headache Acetaminophen (paracetamol) Dipyrone Nonsteroidal anti-inflammatory drugs 15
16 Nonopioid Analgesics NSAIDs Acetaminophen (paracetamol) Minimal anti-inflammatory effects Fewer adverse effects than other nonopioid analgesics Adverse effects Renal toxicity Risk for hepatotoxicity at high doses Increased risk with liver disease or chronic alcoholism No effect on platelet function Mechanism Inhibit both peripheral and central cyclooxygenase, reducing prostaglandin formation 3 isoforms of COX COX-1: Constitutive, physiologic COX-2: Inducible, inflammatory COX-3: Central, blocked by acetaminophen NSAIDs NSAIDs Properties Nonspecific analgesics, but greater effectiveness likely in inflammatory pains Dose-dependent effects, with ceiling dose Marked individual variation in response to different drugs Drug-to-drug variation in toxicities partly determined by COX-1/COX-2 selectivity Properties Adverse effects: GI toxicity, renal toxicity, cardiovascular toxicity, bleeding diathesis, prothrombotic effects GI toxicity reduced by PPIs, misoprostol, and possibly high-dose histamine-2 blockers COX-2 selective inhibitors have better GI safety profile Use with caution in patients with renal insufficiency Use with caution in patients with atherosclerotic disease, congestive heart failure, or hypertension NSAIDs NSAIDs Chemical Class Nonacidic Acidic Salicylates Generic Name nabumetone aspirin, diflunisal, choline magnesium trisalicylate, salsalate Chemical Class Acidic Acetic acids Oxicams Generic Name indomethacin, tolmetin, sulindac, diclofenac, ketorolac meloxicam, piroxicam Proprionic acids ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin Fenamates Selective COX-2 inhibitors mefenamic acid, meclofenamic acid celecoxib 16
17 NSAIDs Adjuvant Analgesics Drug selection should be influenced by drug-selective toxicities, prior experience, convenience, cost Relative cost-benefit of COX-2 selective drugs and nonselective drugs combined with gastroprotective therapy is not known Defined as drugs with other indications that may be analgesic in specific circumstances Numerous drugs in diverse classes Sequential trials are often needed Adjuvant Analgesics Multipurpose Adjuvant Analgesics Multipurpose analgesics Drugs used for neuropathic pain Drugs used for musculoskeletal pain Drugs used for cancer pain Drugs used for headache Class Antidepressants Alpha-2 adrenergic agonists Corticosteroids Examples amitriptyline, desipramine, nortriptyline, duloxetine, venlafaxine, paroxetine, others tizanidine, clonidine prednisone, dexamethasone Multipurpose Adjuvant Analgesics Multipurpose Adjuvant Analgesics Antidepressants Best evidence: 3 0 amine TCAs (e.g., amitriptyline) 2 0 amine TCAs (desipramine, nortriptyline) better tolerated and also analgesic Evidence for the SSNRIs, e.g., duloxetine, and little evidence in favor of SSRIs/atypical antidepressants (e.g., paroxetine, bupropion, others); these are better tolerated yet Alpha-2 adrenergic agonists Clonidine and tizanidine used for chronic pain of any type Tizanidine usually better tolerated Tizanidine starting dose 1 2 mg/d; usual maximum dose up to 40 mg/d 17
18 Adjuvant Analgesics for Neuropathic Pain Adjuvant Analgesics for Neuropathic Pain Class Anticonvulsants lamotrigine carbamazepine, Examples gabapentin, pregabalin, valproate, phenytoin, Class NMDA receptor Antagonists Examples dextromethorphan, ketamine, clonazepam, topiramate, levetiracetam tiagabine, amantadine Miscellaneous baclofen, calcitonin oxcarbazepine, zonisamide Topical lidocaine, Local anesthetics mexiletine, tocainide lidocaine/prilocaine, capsaicin, NSAIDs Adjuvant Analgesics for Neuropathic Pain Anticonvulsants Gabapentin or pregabalin commonly used Favorable safety profile and positive RCTs in PHN/diabetic neuropathy Analgesic effects supported for phenytoin, carbamazepine, valproate, clonazepam, and lamotrigine Limited experience with other drugs Adjuvant Analgesics for Neuropathic Pain Local anesthetics Oral therapy with mexiletine, tocainide, flecainide IV/SQ lidocaine also useful Useful for any type of neuropathic pain Adjuvant Analgesics for Neuropathic Pain Adjuvant Analgesics for Neuropathic Pain Miscellaneous drugs Calcitonin RCTs in CRPS and phantom pain Limited experience Baclofen RCT in trigeminal neuralgia mg/d or higher NMDA-receptor antagonists N-methyl-D-aspartate receptor involved in neuropathic pain Commercially-available drugs are analgesic: ketamine, dextromethorpan, amantadine 18
19 Topical Adjuvant Analgesics Adjuvant Analgesics for Musculoskeletal Pain Used for neuropathic pain Local anesthetics Lidocaine patch Cream, eg, lidocaine 5%, EMLA Capsaicin Used for musculoskeletal pains NSAIDs Muscle relaxants Refers to numerous drugs, eg, cyclobenzaprine, carisoprodol, orphenadrine, methocarbamol, chlorzoxazone, metaxalone Centrally-acting analgesics Do not relax skeletal muscle Adjuvant Analgesics for Cancer Pain Adjuvant Analgesics for Chronic Headache For bone pain Bisphosphonates (eg, pamidronate, clodronate), calcitonin, radiopharmaceuticals (eg, Sr 89, Sm 153 ) For bowel obstruction pain Anticholinergics, octreotide Beta blockers Anticonvulsants Calcium channel blockers Alpha-2 adrenergic agonists Antidepressants Vasoactive drugs ACE inhibitors Pathophysiology Nociceptive pain Neuropathic pain Idiopathic pain Psychogenic pain Commensurate with identifiable tissue damage May be abnormal, unfamiliar pain, probably caused by dysfunction in PNS or CNS Pain, not attributable to identifiable organic or psychologic processes Sustained by psychologic factors Nociceptive Pain Presumably related to ongoing activation of primary afferent neurons in response to noxious stimuli Pain is consistent with the degree of tissue injury Subtypes Somatic: well localized, described as sharp, aching, throbbing Visceral: more diffuse, described as gnawing or cramping 19
20 Neuropathic Pain Pain believed to be sustained by aberrant somatosensory processing in the peripheral or central nervous system Subtypes Central generator Deafferentation pain (central pain, phantom pain) Sympathetically-maintained pain (CRPS) Peripheral generator Originate in the nerve root, plexus, or nerve Polyneuropathies, mononeuropathies Novel Drug Therapies for Pain Central Nociception: Emerging Analgesic Targets Excitatory amino acid and NK receptors N-type Ca ++ receptors N-acetylcholine receptors Adenosine (A 1 ) receptors Cannabinoid (CB1) receptors n-6 HUFA highly unsaturated fatty acids, and trans fatty acid levels higher in CRPS Peripheral Nociception: Emerging Analgesic Targets Sensory neuron specific Na + channels (eg, PN3, NAN) Opioid receptors Vanilloid receptors Serotonin receptors Botox Injections (Joints) unknown mechanism research appears solid Peripheral Nociception: Emerging Analgesic Targets Nonopioid Analgesics and Adjuvants for Inflammatory Neuropathic Pain States Alpha-adrenergic receptors Proton-sensitive channels (ph-sensitive) Nerve growth-factor receptors (TrKA, p75) N- or T-type Ca ++ channels Purine receptors Anticytokines (eg, anti TNF-alpha antibodies, thalidomide, IV bisphosphonates) TrKA = tyrosine kinase 20
21 Adjuvant Analgesics With Opioid Interactions NMDA antagonists (eg, dextromethorphan, ketamine, amantadine) Cholecystokinin-B antagonists (eg, proglumide) Ultra-low doses of opioid antagonists 21
Pharmacotherapy of Pain SUPHAT SUBONGKOT, PHARM.D. BCOP, BCOP CLINICAL PHARMACY DIVISION KHON KAEN UNIVERSITY, THAILAND
Pharmacotherapy of Pain SUPHAT SUBONGKOT, PHARM.D. BCOP, BCOP CLINICAL PHARMACY DIVISION KHON KAEN UNIVERSITY, THAILAND Therapeutic Strategies for Pain and Disability Pharmacotherapy Rehabilitative approaches
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationSpinal Cord Injury Pain. Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018
Spinal Cord Injury Pain Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018 Objectives At the conclusion of this session, participants should be able to: 1. Understand the difference between nociceptive
More informationCurrent Pharmacotherapy of Chronic Pain
S16 Journal of Pain and Symptom Management Vol. 19 No. 1(Suppl.) January 2000 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia Current Pharmacotherapy of Chronic Pain Russell
More informationPain control in Cancer patients. Dr Ali Shoeibi, Assistant Professor of Neurology
Pain control in Cancer patients Dr Ali Shoeibi, Assistant Professor of Neurology More than two thirds of patients with advanced cancer experience cancer pain Almost all pain can be controlled to some extent
More informationNeuropathic Pain. Scott Magnuson, MD Pain Management of North Idaho, PLLC
Neuropathic Pain Scott Magnuson, MD Pain Management of North Idaho, PLLC Pain is our friend "An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described
More informationDisclosures. Outline of Session 5/18/12. Chronic Pain in Children: Pharmacologic and Other Interventions. Pain: Increasing Awareness
5/18/12 Disclosures Chronic Pain in Children: Pharmacologic and Other Interventions I have nothing to disclose Maurice S Zwass, MD Professor of Anesthesia and Pediatrics, UCSF Outline of Session Pain:
More informationAcute Pain NETP: SEPTEMBER 2013 COHORT
Acute Pain NETP: SEPTEMBER 2013 COHORT Pain & Suffering an unpleasant sensory & emotional experience associated with actual or potential tissue damage, or described in terms of such damage International
More informationRational Polypharmacy
Rational Polypharmacy Thomas B. Gregory, PharmD, BCPS, CPE, FASPE Disclosures Clinical advisory board: Daiichi Sankyo 1 Introduction Cox Health Ambulatory Pain Clinic Pharmacy Specialist Learning Objectives
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More information3/1/2018. Disclosures. Objectives. Clinical advisory board member- Daiichi Sankyo
Adjuvant pain medications in geriatrics Thomas B. Gregory, Pharm.D., BCPS, CPE, FASPE Clinical Pharmacy Specialist Pain Management CoxHealth Springfield, MO Disclosures Clinical advisory board member-
More informationNeuropathic Pain in Palliative Care
Neuropathic Pain in Palliative Care Neuropathic Pain in Advanced Cancer Affects 40% of patients Multiple concurrent pains are common Often complex pathophysiology with mixed components Nocioceptive Neuropathic
More informationPOST OPERATIVE PAIN MANAGEMENT: PAIN AND COMPLICATIONS
POST OPERATIVE PAIN MANAGEMENT: PAIN AND COMPLICATIONS November 9, 2018 Aimee LaMere, CNP Molly McNaughton, CNP Leslie Weide, MSW, LICSW, ACM Disclosures: Conflict of interest statement: We certify that,
More informationAssociate Professor Supranee Niruthisard Department of Anesthesiology Faculty of Medicine Chulalongkorn University January 21, 2008
Associate Professor Supranee Niruthisard Department of Anesthesiology Faculty of Medicine Chulalongkorn University January 21, 2008 PAIN MECHANISMS Somatic Nociceptive Visceral Inflammatory response sensitizes
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationNSG 3008A: PROFESSIONAL NURSING TRANSITION. Objectives NATURE OF PAIN. Pain is key to the survival of an organism
NSG 3008A: PROFESSIONAL NURSING TRANSITION PAIN MANAGEMENT: STRESS ADAPTATION; CULTURAL DIVERSITY; SUBSTANCE ABUSE AND ETHICAL ISSUES Objectives 1. Describe the physiology of pain and related theories
More informationPharmacological treatment of Pain
Pharmacological treatment of Pain None Disclosures and Conflict of Interest Dr John F. Flannery Medical Director MSK and Multisystem Rehab Program PMR - FRCPC Objectives At the end of this presentation
More informationManagement of Pain related to Spinal Cord Lesion
Management of Pain related to Spinal Cord Lesion A Neurologist s Perspective Vincent Mok, MD Associate Professor Division of Neurology Department of Medicine and Therapeutics The Chinese University of
More informationCancer Pain. Suresh K Reddy, MD,FFARCS The University of Texas MD Anderson Cancer Center
Cancer Pain Suresh K Reddy, MD,FFARCS The University of Texas MD Anderson Cancer Center Prevalence of the Most Common Symptoms in Advanced Cancer (1000 Adults) Symptom % Symptom % Pain 82 Lack of Energy
More informationPain Assessment & Management. For General Nursing Orientation
Pain Assessment & Management For General Nursing Orientation April 2012 Overview Definition of pain Barriers to effective pain management Types of pain Objective pain assessment Approaches to management
More informationA Pain Management Primer for Pharmacists. Jessica Geiger-Hayes, PharmD, BCPS, CPE Andrea Wetshtein, PharmD, BCPS, CPE
A Pain Management Primer for Pharmacists Jessica Geiger-Hayes, PharmD, BCPS, CPE Andrea Wetshtein, PharmD, BCPS, CPE Objectives Discuss the differences between somatic, visceral, and neuropathic pain Design
More informationNon-opioid and adjuvant pain management
Non-opioid and adjuvant pain management ALLISON JORDAN, MD, HMDC MEDICAL DIRECTOR OF PALLIATIVE CARE SERVICES CHRISTIAN AND ALTON MEMORIAL HOSPITALS ASSOCIATE MEDICAL DIRECTOR, BJC HOSPICE ASSISTANT PROFESSOR
More informationGUIDELINES ON PAIN MANAGEMENT IN UROLOGY
GUIDELINES ON PAIN MANAGEMENT IN UROLOGY F. Francesca (chairman), P. Bader, D. Echtle, F. Giunta, J. Williams Eur Urol 2003; 44(4):383-389 Introduction Pain is defined as an unpleasant sensory and emotional
More informationUCSF Pediatric Hospital Medicine Boot Camp Pain Session 6/21/14. Cynthia Kim and Stephen Wilson
UCSF Pediatric Hospital Medicine Boot Camp Pain Session 6/21/14 Cynthia Kim and Stephen Wilson Rules Buzz first and player answers If answer correct, then the player asks teammates if they want to keep
More informationNeuropathic Pain and Pain Management Options. Mihnea Dumitrescu, MD
Neuropathic Pain and Pain Management Options Mihnea Dumitrescu, MD www.austinppc.com International Association for the Study of Pain (IASP): Definition of Pain Pain is an unpleasant sensory and emotional
More informationPharmacology of Pain Transmission and Modulation
Pharmacology of Pain Transmission and Modulation 2 Jürg Schliessbach and Konrad Maurer Nociceptive Nerve Fibers Pain is transmitted to the central nervous system via thinly myelinated Aδ and unmyelinated
More informationPain Pathways. Dr Sameer Gupta Consultant in Anaesthesia and Pain Management, NGH
Pain Pathways Dr Sameer Gupta Consultant in Anaesthesia and Pain Management, NGH Objective To give you a simplistic and basic concepts of pain pathways to help understand the complex issue of pain Pain
More informationSteven Richeimer, M.D.
Steven Richeimer, M.D. Associate Professor of Anesthesiology & Psychiatry Chief, Division of Pain Medicine Keck School of Medicine, USC Los Angeles, CA 323-442-6202 www.helpforpain.com Pain Light touch
More informationPain Management: A Comprehensive Review
Pain Management: A Comprehensive Review 1) Pain related issues currently account for approximately of doctor s visits. a) 60% b) 70% c) 80% d) 90% 2) Which pain scale is frequently utilized with children?
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationPain Management: A Comprehensive Review
Pain Management: A Comprehensive Review 1) Pain related issues currently account for approximately of doctor s visits. a) 60% b) 70% c) 80% d) 90% 2) Which pain scale is frequently utilized with children?
More informationPAIN MANAGEMENT IN UROLOGY
24 PAIN MANAGEMENT IN UROLOGY F. Francesca (chairman), P. Bader, D. Echtle, F. Giunta, J. Williams Eur Urol 2003; 44(4):383-389 Introduction Pain is defined as an unpleasant sensory and emotional experience
More informationChoose a category. You will be given the answer. You must give the correct question. Click to begin.
Instructions for using this template. Remember this is Jeopardy, so where I have written Answer this is the prompt the students will see, and where I have Question should be the student s response. To
More informationMedications for the Treatment of Neuropathic Pain
Medications for the Treatment of Neuropathic Pain February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation Neuropathic Pain Pain, paresthesias, and sensory
More informationAnalgesics and Adjuvants for Pain Therapy
Topics to be covered Analgesics and Adjuvants for Pain Therapy Chuthamanee C. Suthisisang BPharm, PhD Department of Pharmacology Faculty of Pharmacy Mahidol University Neurochemistry of pain Early pain
More informationNociceptive Pain. Pathophysiologic Pain. Types of Pain. At Presentation. At Presentation. Nonpharmacologic Therapy. Modulation
Learning Objectives Effective, Safe Analgesia An Approach to Appropriate Outpatient Chronic Pain Treatment By the end of this presentation, participants will be able to: Identify multiple factors that
More informationTreatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am
Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Tim R Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Cleveland Clinic Akron General Center for Family
More informationSomatosensory Physiology (Pain And Temperature) Richard M. Costanzo, Ph.D.
Somatosensory Physiology (Pain And Temperature) Richard M. Costanzo, Ph.D. OBJECTIVES After studying the material of this lecture the student should be familiar with: 1. The relationship between nociception
More informationInterprofessional Webinar Series
Interprofessional Webinar Series Drug Therapy for Neuropathic Pain in the Medically Ill Russell K. Portenoy, MD Executive Director, MJHS Institute for Innovation in Palliative Care Chief Medical Officer,
More informationADJUVANT PAIN MANAGEMENT
ADJUVANT PAIN MANAGEMENT Bruce H. Chamberlain, MD FACP FAAHPM Palliative Consulting Orem, UT AAHPM Intensive Board Review Course Using Adjuvant Treatments for Chronic Pain Bruce H. Chamberlain, MD FACP
More informationPalliative Care: Treatment at the End of Life
Page 1 Palliative Care: Treatment at the End of Life This webcast has been supported by an educational grant from Purdue Pharma L.P. Mary Lynn McPherson, Pharm.D., BCPS, CDE Professor, University of Maryland
More informationReceptors and Neurotransmitters: It Sounds Greek to Me. Agenda. What We Know About Pain 9/7/2012
Receptors and Neurotransmitters: It Sounds Greek to Me Cathy Carlson, PhD, RN Northern Illinois University Agenda We will be going through this lecture on basic pain physiology using analogies, mnemonics,
More informationPAIN MANAGEMENT STRATEGIES: ALTERNATIVES TO OPIOIDS
PAIN MANAGEMENT STRATEGIES: ALTERNATIVES TO OPIOIDS SATURDAY/2:00-3:00PM ACPE UAN: 0107-9999-17-239-L01-P 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists: Upon completion
More informationComplex Acute Surgical Pain Management. Thomas Baribeault MSN, CRNA
Complex Acute Surgical Pain Management Thomas Baribeault MSN, CRNA Introduction Anatomy and pathophysiology of acute surgical pain Pharmacology Chronic pain patient Opioid tolerant patient Introduction
More informationPAIN & ANALGESIA. often accompanied by clinical depression. fibromyalgia, chronic fatigue, etc. COX 1, COX 2, and COX 3 (a variant of COX 1)
Pain - subjective experience associated with detection of tissue damage ( nociception ) acute - serves as a warning chronic - nociception gone bad often accompanied by clinical depression fibromyalgia,
More informationPeripheral neuropathy (PN)
Peripheral neuropathy (PN) damage or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of health, depending on the type of nerve affected o chronic:
More informationDisclosures. Management of Chronic, Non- Terminal Pain. Learning Objectives. Outline. Drug Schedules. Applicable State Laws
Disclosures Management of Chronic, Non- Terminal Pain No financial disclosures or conflicts of interest to report Michael A. Smith, PharmD, BCPS Clinical Assistant Professor, University of Michigan College
More informationPAIN IS A SUBJECTIVE EXPERIENCE: It is not a stimulus. MAJOR FEATURES OF THE PAIN EXPERIENCE: Sensory discriminative Affective (emotional) Cognitive
PAIN PAIN IS A SUBJECTIVE EXPERIENCE: It is not a stimulus MAJOR FEATURES OF THE PAIN EXPERIENCE: Sensory discriminative Affective (emotional) Cognitive MEASUREMENT OF PAIN: A BIG PROBLEM Worst pain ever
More information9/30/2017. Case Study: Complete Pain Assessment and Multimodal Approach to Pain Management. Program Objectives. Impact of Poorly Managed Pain
Case Study: Complete Pain Assessment and Multimodal Approach to Pain Management MARY BETH PARTYKA MSN ADULT NURSE PRACTITIONER ADVOCATE CHRIST MEDICAL CENTER ADULT PAIN SERVICE Program Objectives Identify
More informationUnderstanding pain and mental illness Impact on management principles
Understanding pain and mental illness Impact on management principles Chris Alderman Consultant Psychopharmacologist Pain and mental illness - context PAIN MENTAL ILLNESS OTHER FACTORS (personality, history.
More informationThe biochemical origin of pain: The origin of all pain is inflammation and the inflammatory response: Inflammatory profile of pain syndromes
The biochemical origin of pain: The origin of all pain is inflammation and the inflammatory response: Inflammatory profile of pain syndromes 1 Medical Hypothesis 2007, Vol. 69, pp. 1169 1178 Sota Omoigui
More informationAmber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center
Pharmacologic Management of Pain Amber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center Objectives Identify types of
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More informationPrescription Pain Management. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita 1 Narciso Pharm D
Prescription Pain Management University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita 1 Narciso Pharm D 2 Objectives Understand how to preform a pain assessment Know which medications
More informationOverview of Neuropathic pain
Overview of Neuropathic pain Kongkiat Kulkantrakorn,M.D. Neurology division Thammasat University 1 Contents Overview of pain New concepts and mechanism Treatment options New data in management 2 3 Breaking
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress REDUCING THE PAIN FACTOR AN UPDATE ON PERI-OPERATIVE ANALGESIA Sandra Forysth, BVSc DipACVA Institute of Veterinary,
More informationPain Signaling Neuropathic Pain Distinctly different from nociceptive pain Sustained by abnormal processing of sensory input by the peripheral or cent
Objectives Pharmacologic Management of Neuropathic Pain Joseph R. Ineck, Pharm.D.,., CPE Pharmacist: St. Luke s Health System At the conclusion of this presentation, pharmacists will be able to: 1. Differentiate
More informationChronic Pain Overview. Mark S. Wallace, M.D. Professor of Clinical Anesthesiology University of California, San Diego
Chronic Pain Overview Mark S. Wallace, M.D. Professor of Clinical Anesthesiology University of California, San Diego Physiology of Pain Perception CORE Transduction Transmission Modulation Perception Interpretation
More informationPain. November 1, 2006 Dr. Jana Pilkey MD, FRCP(C) Internal Medicine, Palliative Medicine
Pain November 1, 2006 Dr. Jana Pilkey MD, FRCP(C) Internal Medicine, Palliative Medicine Objectives To be able to define pain To be able to evaluate pain To be able to classify types of pain To learn appropriate
More informationBEYOND OPIOIDS: ADJUNCTS FOR TREATING PAIN
BEYOND OPIOIDS: ADJUNCTS FOR TREATING PAIN Ronald Januchowski, D.O. 2017 Objectives By the end of the presentation, the learner should be able to: Summarize the risks of opiates when used for non-cancer
More informationSan Francisco Chronicle, June 2001
PAIN San Francisco Chronicle, June 2001 CONGENITAL INSENSITIVITY TO PAIN PAIN IS A SUBJECTIVE EXPERIENCE: It is not a stimulus MAJOR FEATURES OF THE PAIN EXPERIENCE: Sensory discriminative Affective (emotional)
More information21 st June BDS BASHD Therapeutics Pain and Analgesia. BASHD Therapeutics Analgesics and Pain Management. Links to other BASHD content
Volume of Prescribing by Dentists 2011 ( a reminder) BASHD Therapeutics Analgesics and Pain Management Analgesics account for 1 in 80 dental prescriptions made A lot more analgesics will be suggested for
More informationBrian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD
Brian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD 1630 Main Street Suite 215 Chester, MD 410-571-9000 www.4-no-pain.com
More informationCHAMP: Bedside Teaching TREATING PAIN. Stacie Levine MD. What is the approach to treating pain in the aging adult patient?
CHAMP: Bedside Teaching TREATING PAIN Stacie Levine MD Teaching Trigger: An older adult patient is identified as having pain. Clinical Question: What is the approach to treating pain in the aging adult
More informationPERIOPERATIVE PAIN MANAGEMENT: WHAT S UP WITH METHADONE?
PERIOPERATIVE PAIN MANAGEMENT: WHAT S UP WITH METHADONE? Sandra Z Perkowski, VMD, PhD, DACVAA University of Pennsylvania, School of Veterinary Medicine, Philadelphia, PA Pre-emptive and multimodal use
More information2018 Learning Outcomes
I. Pain Physiology and Anatomy (20%) A. Describe the basic anatomy of the nervous system. B. Describe the physiological mechanisms of neuronal function (eg- action potentials). C. Review the nociceptive
More informationThe Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI
More informationPAIN. Physiology of pain relating to pain management
PAIN Physiology of pain relating to pain management What is pain? An unpleasant sensory and emotional experience associated with actual or potential tissue damage. (Melzac and Wall) The generation of pain
More informationPractical Pain Management Leah Centanni, MSN, FNP-C, Asst. Clinical Professor CANP Conference March 22, 2014
Practical Pain Management Leah Centanni, MSN, FNP-C, Asst. Clinical Professor CANP Conference March 22, 2014 Overview Types of Pain Physical Examination of Pain Pharmacologic Approach in Pain Management
More information211MDS Pain theories
211MDS Pain theories Definition In 1986, the International Association for the Study of Pain (IASP) defined pain as a sensory and emotional experience associated with real or potential injuries, or described
More informationReview Normal Pain Anatomy and Physiology Pathological Pain Pathways? Targeted Treatments Future Developments 9/26/2011
Jeremy A. Adler, MS, PA C Pacific Pain Medicine Consultants Encinitas, CA Consultant Pfizer Endo Pharmaceuticals Azur Pharma Janssen Pharmaceuticals St. Jude Medical As part of this presentation, off label
More informationFibromyalgia: Current Trends and Concepts
Fibromyalgia: Current Trends and Concepts Dr. Brian Kahan Fellow American Academy of Physical Medicine and Rehabilitation Diplomat American Academy of Pain Medicine American College of Rheumatology (ACR)
More informationsensory nerves, motor nerves, autonomic nerves
damage or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of health, depending on the type of nerve affected o chronic: long term, begins subtly
More informationManaging Pain after Transplant Denice Economou, RN,MN,CHPN,AOCN
Managing Pain after Transplant Denice Economou, RN,MN,CHPN,AOCN Oncology Clinical Nurse Specialist, Senior Research Specialist City of Hope Definition of Pain Pain is an unpleasant sensory and emotional
More informationin this web service Cambridge University Press
Prescriber's Guide in this web service in this web service Essential Pain Pharmacology The Prescriber's Guide Howard S. Smith Professor of Anesthesiology, Internal Medicine, Physical Medicine and Rehabilitation,
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationManagement of Pain. Agenda: Definitions Pathophysiology Analgesics
C. Brian Warriner, MD, FRCPC Professor and Past Chair UBC Department of Anesthesiology, Pharmacology and Therapeutics brian.warriner@vch.ca Agenda: Definitions Pathophysiology Analgesics Gases(N 2 O) Opiates
More informationIntroduction to some interesting research questions: Molecular biology of the primary afferent nociceptor
Introduction to some interesting research questions: Molecular biology of the primary afferent nociceptor NOCICEPTORS ARE NOT IDENTICAL PEPTIDE SubP/CGRP Trk A NON-PEPTIDE IB4 P2X 3 c-ret Snider and McMahon
More informationPain Management Strategies Webinar/Teleconference
Pain Management Strategies Webinar/Teleconference Barry K. Baines, MD April 16, 2009 Objectives Describe the principles of pain management. Identify considerations in the use of opioids. Describe the benefits
More informationPathophysiology of Pain
Pathophysiology of Pain Wound Inflammatory response Chemical mediators Activity in Pain Path PAIN http://neuroscience.uth.tmc.edu/s2/chapter08.html Chris Cohan, Ph.D. Dept. of Pathology/Anat Sci University
More informationAnalgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I. Mr.D.Raju,M.pharm, Lecturer
Analgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I Mr.D.Raju,M.pharm, Lecturer Mechanisms of Pain and Nociception Nociception is the mechanism whereby noxious peripheral stimuli are transmitted to
More informationChapter 16. Sense of Pain
Chapter 16 Sense of Pain Pain Discomfort caused by tissue injury or noxious stimulation, and typically leading to evasive action important /// helps to protect us lost of pain in diabetes mellitus = diabetic
More informationNarcotic Analgesics. Jacqueline Morgan March 22, 2017
Narcotic Analgesics Jacqueline Morgan March 22, 2017 Pain Unpleasant sensory and emotional experience with actual or potential tissue damage Universal, complex, subjective experience Number one reason
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationNon-Opioid Drugs to Treat Neuropathic Pain. March 2018
Non-Opioid Drugs to Treat Neuropathic Pain Final Report March 2018 This report is intended only for state employees in states participating in the Drug Effectiveness Review Project (DERP). Do not distribute
More informationOptimizing Neuropathic Pain Medications. Dermot More-O Ferrall, MD
Optimizing Neuropathic Pain Medications Dermot More-O Ferrall, MD PAIN MANAGEMENT OPIOID DISPENSING Objectives Understand: Definition and subtypes of pain Pathophysiology of neuropathic pain Pharmacologic
More informationDisclosures. Objectives 9/8/2015
The Aftermath of the Decade of Pain: Alternatives to Opioids in Chronic Pain Management Julie Cunningham, PharmD, BCPP Disclosures No relevant financial disclosures I will discuss off-label uses of antiepileptics,
More informationCorporate Medical Policy
Corporate Medical Policy Intravenous Anesthetics for the Treatment of Chronic Pain File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intravenous_anesthetics_for_the_treatment_of_chronic_pain
More informationSyllabus. Questions may appear on any of the topics below: I. Multidimensional Nature of Pain
Questions may appear on any of the topics below: I. Multidimensional Nature of Pain Syllabus A. Epidemiology 1. Pain as a public health problem with social, ethical, legal and economic consequences 2.
More informationNo Pain, No Gain Pharmacy Patient Pain Counseling Competition
No Pain, No Gain Pharmacy Patient Pain Counseling Competition Offered by the Maine Pharmacy Association as part of the 2010 MPA Fall Conference Sponsored by an educational grant by NASPA and Purdue Pharma,
More informationPathophysiology of Pain. Ramon Go MD Assistant Professor Anesthesiology and Pain medicine NYP-CUMC
Pathophysiology of Pain Ramon Go MD Assistant Professor Anesthesiology and Pain medicine NYP-CUMC Learning Objectives Anatomic pathway of nociception Discuss the multiple target sites of pharmacological
More information3/7/2018. IASP updated definition of pain. Nociceptive Pain. Transduction. (Nociceptors) Transmission. (Peripheral nerve) Modulation
IASP updated definition of pain The Pain of Trauma and The Trauma of Pain: The Opioid Crisis is Not What You Think. Bennet Davis, M.D. Many people report pain in the absence of tissue damage or any likely
More informationeappendix A. Opioids and Nonsteroidal Anti-Inflammatory Drugs
eappendix A. Opioids and Nonsteroidal Anti-Inflammatory Drugs Nonsteroidal Anti-Inflammatory Drugs Nonselective nonsteroidal anti-inflammatory drugs Diclofenac, etodolac, flurbiprofen, ketorolac, ibuprofen,
More informationPain teaching. Muhammad Laklouk
Pain teaching Muhammad Laklouk Definition Pain An unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. Sensory (discriminatiory)
More informationAKA a painful lecture by Colleen Blanchfield, MD Full Circle Neuropsychiatric Wellness Center
A lecture on PAIN AKA a painful lecture by Colleen Blanchfield, MD Full Circle Neuropsychiatric Wellness Center 1 Overview of the lecture Anatomy of the Pain Tract How a painful stimulus travels from the
More informationSYLLABUS SPRING 2011 COURSE: NSC NEUROBIOLOGY OF PAIN
SYLLABUS NSC 4358 NEUROBIOLOGY OF PAIN SPRING 2011 1 SYLLABUS SPRING 2011 COURSE: NSC 4358 001 NEUROBIOLOGY OF PAIN Instructor: Aage R. Møller PhD E-mail: AMOLLER@UTDALLAS.EDU Class schedule: Main Campus:
More informationBASICS OF OPIOID PRESCRIBING 10:30-11:45AM
PROVIDING QUALITY CARE TO PAIN PATIENTS IN IOWA BASICS OF OPIOID PRESCRIBING 10:30-11:45AM ACPE UAN: 107-000-14-013-L01-P Activity Type: Application-Based 0.125 CEU/1.25hr Learning Objectives for Pharmacists:
More information